| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| TAK-243 | TAK-243; MLN-7243 | Phase 1 Clinical | Takeda Pharmaceutical Co Ltd | Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Solid tumours | Details |